The estimated Net Worth of Christine Berni Silverstein is at least $1.49 Million dollars as of 17 June 2024. Ms. Silverstein owns over 25,821 units of Abeona Therapeutics Inc stock worth over $346,932 and over the last 6 years she sold ABEO stock worth over $141,203. In addition, she makes $1,000,220 as Director at Abeona Therapeutics Inc.
Christine has made over 2 trades of the Abeona Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 25,821 units of ABEO stock worth $116,453 on 17 June 2024.
The largest trade she's ever made was selling 25,821 units of Abeona Therapeutics Inc stock on 17 June 2024 worth over $116,453. On average, Christine trades about 2,143 units every 18 days since 2019. As of 17 June 2024 she still owns at least 62,063 units of Abeona Therapeutics Inc stock.
You can see the complete history of Ms. Silverstein stock trades at the bottom of the page.
Christine Berni Silverstein serves as Director of the Company. Ms. Silverstein became our Chief Financial Officer on January 7, 2019. Ms. Silverstein transitioned to Chief Financial Officer from Senior Vice President of Finance & Investor Relations, in January 2019 and brings 15 years of experience in capital markets strategy, financial services, investor relations and healthcare media communications to the Company. Prior to joining Abeona, she served as Head of Investor Relations at Relmada Therapeutics, Inc., a clinical stage, publicly-traded specialty pharmaceutical company. Before that, Ms. Silverstein was a Managing Director at SCO Financial Group, a New York-based corporate advisory firm, where she focused efforts on helping clients build robust investor relations infrastructures and providing strategic financial counsel. Earlier in her career, she held senior positions at two boutique New York investor and public relations agencies, The Investor Relations Group (IRG) and Corporate Profile LLC. Ms. Silverstein’s core focus during her agency tenure included consulting C-level management on capital markets strategies, media, fundraising initiatives, crisis management and regulatory issues. She began her career in the financial services as a registered investment advisor (RIA) at Royal Alliance Associates before moving to the investor and corporate relations industry. A member of the National Investor Relations Institute, Ms. Silverstein holds a B.S. from the Peter Tobin College of Business at St. John’s University. Senior Vice President, Investor Relations & Finance
As the Director of Abeona Therapeutics Inc, the total compensation of Christine Silverstein at Abeona Therapeutics Inc is $1,000,220. There are no executives at Abeona Therapeutics Inc getting paid more.
Christine Silverstein is 37, she's been the Director of Abeona Therapeutics Inc since 2020. There are 7 older and no younger executives at Abeona Therapeutics Inc. The oldest executive at Abeona Therapeutics Inc is Jon Voss, 61, who is the VP & Head of Quality.
Christine's mailing address filed with the SEC is 6555 CARNEGIE AVE, 4TH FLOOR, , CLEVELAND, OH, 44103.
Over the last 15 years, insiders at Abeona Therapeutics Inc have traded over $4,486,735 worth of Abeona Therapeutics Inc stock and bought 427,809 units worth $1,765,143 . The most active insiders traders include Capital Partners Llc Rouhan..., Todd Wider, and Michael Amoroso. On average, Abeona Therapeutics Inc executives and independent directors trade stock every 50 days with the average trade being worth of $256,542. The most recent stock trade was executed by Mark Alvino on 17 June 2024, trading 25,890 units of ABEO stock currently worth $116,764.
abeona therapeutics inc. (nasdaq: $abeo), is a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases. abeona was forged from the company’s close collaborations with key stakeholders all dedicated to transforming new biotechnology insights into breakthrough treatments for rare diseases. abeona's lead programs include abo-102 (aav-sgsh), an adeno-associated virus (aav) based gene therapy for sanfilippo syndrome type a (mps iiia) and eb-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (rdeb). abeona is also developing abo-101 (aav-naglu) for sanfilippo syndrome type b (mps iiib), abo-201 (aav-cln3) gene therapy for juvenile batten disease (jncl), abo-202 (aav-cln1) for treatment of infantile batten disease (incl), eb-201 for epidermolysis bullosa (eb), abo-301 (aav-fancc) for fanconi anemia (fa) disorder and abo-302 using a novel crispr/cas9-based gene editing approach to gene t
Abeona Therapeutics Inc executives and other stock owners filed with the SEC include: